天坛生物：下属企业成都蓉生收到药品GMP符合性检查告知书

Group 1 - The core point of the article is that TianTan Biological (600161.SH) announced that its subsidiary Chengdu Rongsheng received a GMP compliance inspection notice from the Sichuan Provincial Drug Administration [1] - The inspection covered the production workshop and related areas for blood products (subcutaneous human immunoglobulin) [1] - Chengdu Rongsheng's blood product production workshop meets national GMP requirements and can commence production after obtaining the relevant registration certificate and production license [1] Group 2 - The product has completed Phase III clinical trials and a marketing authorization application has been submitted [1] - Future production may be influenced by various factors, indicating uncertainty [1]